• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Amgen

Amgen

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37

    Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37

  2. MARKET SNAPSHOT: U.S. Markets: Futures Up With Twitter, GDP, Fed In Focus

    MARKET SNAPSHOT: U.S. Markets: Futures Up With Twitter, GDP, Fed In Focus

  3. UPDATE: U.S. markets: Futures up with Twitter, GDP, Fed in focus

    UPDATE: U.S. markets: Futures up with Twitter, GDP, Fed in focus

  4. U.S. markets: Futures up with Twitter, GDP, Fed in focus

    U.S. markets: Futures up with Twitter, GDP, Fed in focus

  5. UPDATE: Twitter soars on results; Yelp gains ahead of earnings

    UPDATE: Twitter soars on results; Yelp gains ahead of earnings

  6. UPDATE: Darden rises after CEO steps down; Herbalife tumbles

    UPDATE: Darden rises after CEO steps down; Herbalife tumbles

  7. UPDATE: Herbalife sinks on disappointing results; Darden gains

    UPDATE: Herbalife sinks on disappointing results; Darden gains

  8. U.S. Stocks Gain After Fed Statement

    U.S. Stocks Gain After Fed Statement

  9. Bayer Receives EU Approval for Stivarga for Tumor Treatment

    Bayer Receives EU Approval for Stivarga for Tumor Treatment

  10. Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer

    Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.